Syn th esis a n d Ch a r a cter iza tion of
N1-(4-Tolu en esu lfon yl)-N1-
(9-a n th r a cen em eth yl)tr ia m in es
Chaojie Wang, Khalil A. Abboud,† and
Otto Phanstiel IV*
Department of Chemistry, University of Florida, Gainesville,
Florida 32611, and Department of Chemistry, University of
Central Florida, Orlando, Florida 32816-2366
F IGURE 1. The native polyamines.
ophansti@mail.ucf.edu
Received May 13, 2002
Abstr a ct: A modular synthetic approach was developed to
access triamines with varying tether lengths from com-
mercially available aminoalkanols. Initial N-alkylation via
reductive amination with anthracene-9-carbaldehyde pro-
vided the secondary amines in good yield. Subsequent
ditosylation with excess TsCl yielded the respective bis-N,O-
tosylates. The tosylates were reacted with excess putrescine
to give the final triamines. X-ray crystallography revealed
that the polyamine tail is preferentially oriented over the
shielding cone of the anthracene ring.
F IGURE 2. Acridine-spermidine (4) and anthracene-sper-
midine (5) conjugates.
The naturally occuring linear polyamines 1-3 (pu-
trescine, spermidine, and spermine, respectively) have
attracted attention because of their unique biological
properties and potential as therapeutic templates (Figure
1). Indeed, new polyamine homologues have provided a
better understanding of polyamine transport into leuke-
mia cells.1 Structure-activity relationships have provided
important molecular recognition information about the
transporter, which can facilitate future drug design.
Previous polyamine structural changes included terminal
N-alkylation, alteration of the methylene tether between
nitrogens, and attachment of drug “cargoes” to the
polyamine platform.1-4
Polyamines exist as polycations in vivo and have a high
affinity for biological polyanions such as DNA.2 In addi-
tion, flat polycyclic aromatic systems such as the an-
thracene and acridine nuclei interact with DNA as minor
groove binders or DNA intercalators.3 Indeed, bioconju-
gates involving polyamines and these aromatic nuclei (4
and 5 in Figure 2) have been shown to be efficient
topoisomerase II (Topo-II) inhibitors.4 Interestingly, even
though the acridine conjugates 4 were more potent Topo-
II inhibitors in vitro, the related anthracene conjugates
5 were more efficient in a whole cell assay involving
L1210 murine leukemia cells. Spermidine protection
assays suggested that the affinity of these conjugates for
the L1210 polyamine transporter could be modulated via
alterations in the appended polyamine architecture.4
As part of our continuing investigation of polyamine-
anthracene conjugates, we were interested in the size
limitations of the transporter. In other words, what were
the size constraints of materials with use of the polyamine
transport apparatus? How large a drug cargo could be
delivered via this transporter? Could a polyamine struc-
tural change overcome these constraints? As earlier work
pointed to the fact that one could enhance uptake by
modifying the polyamine structure, homologous spermi-
dine derivatives were synthesized.
* Address correspondence to this author at the University of
Central Florida.
The commercially available amino alcohols were en-
visioned as versatile synthetic intermediates. Previous
reports have shown that successive N-alkylation and
mesylation steps can be used to construct the linear
polyamine chain.5 In this report, a modular synthetic
approach was developed to access polyamine architec-
tures with varying tether distances between the nitro-
gens and a large N-tosyl-N-(9-anthracenemethyl) ap-
pended “cargo”. In this manner, a series of anthracene-
polyamine conjugates were prepared for later biological
evaluation. In addition to introducing large steric con-
straints, the tosyl group also imparted interesting long-
distance effects on the appended polyamine chain.
† University of Florida.
(1) For recent reviews about the synthesis and biological properties
of polyamine derivatives see: (a) Casero, R. A., J r.; Woster, P. M. J .
Med. Chem. 2001, 44, 1-26. (b) Karigiannis, G.; Papaioannou, D. Eur.
J . Org. Chem. 2000, 10, 1841-1863. (c) Kuksa, V.; Buchan, R.; Lin, P.
K. T. Synthesis 2000, 9, 1189-1207. (d) Bergeron, R. J .; Feng, Y.;
Weimar, W. R.; McManis, J . S.; Dimova, H.; Porter, C.; Raisler, B.;
Phanstiel, O., IV J . Med. Chem. 1997, 40, 1475-1494. (e) Seiler, N.;
Delcros, J .-G.; Moulinoux, J . P. Int. J . Biochem. Cell Biol. 1996, 28
(8), 843-861.
(2) Geall, A. J .; Blagbrough, I. S. Tetrahedron 2000, 56, 2449-2460.
(3) (a) Kumar, C. V.; Asuncion, E. H. J . Am. Chem. Soc. 1993, 115,
8547-8553. (b) Burr-Furlong, N.; Sato, J .; Grown, T.; Chavez, F.;
Hurlbert, R. B. Cancer Res. 1978, 38, 1329-1335. (c) Gormley, P. E.;
Sethi, V. S.; Cysyk, R. L. Cancer Res. 1978, 38, 1300-1306.
(4) (a) Phanstiel, O., IV; Price, H. L.; Wang, L.; J uusola, J .; Kline,
M.; Shah, S. M. J . Org. Chem. 2000, 65, 5590-5599. (b) Wang, L.;
Price, H. L.; J uusola, J .; Kline, M.; Phanstiel, O., IV J . Med. Chem.
2001, 44, 3682-3691.
(5) Rajeev, K. G.; Sanjayan, G. J .; Ganesh, K. N. J . Org. Chem. 1997,
62, 5169-5173.
10.1021/jo020331p CCC: $22.00 © 2002 American Chemical Society
Published on Web 10/11/2002
J . Org. Chem. 2002, 67, 7865-7868
7865